drugset / Trial / NCT00003090

Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer

NCT00003090 ↗

Phase 2 Unknown 30 enrolled Cancer Biotherapy Research Group
Treatment

Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill non-small cell lung cancer cells. PURPOSE: Phase II trial to study the effect of biological therapy with interleukin-2 in patients with previously treated non-small cell lung cancer.

Timeline

Start
1996-01
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic — —

Indications